Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Verona confirms Serie A status for another year after beating Salernitana
Homes catch fire as lava spills onto town in Iceland
What we're watching: The Great
Nine apologises for using digitally altered image of Animal Justice Party MP Georgie Purcell
Australia, New Zealand send planes to evacuate nationals from New Caledonia
Foreign Affairs Minister Winston Peters to resume 'Pacific reset' plan again
Otago councillors vote to delay notification of controversial land, water plan
Former Pakistan PM Imran Khan gets 10
California congressman urges closer consultation with tribes on offshore wind
China gives monks a list of things they can’t do after the Dalai Lama's death — Radio Free Asia
Verona confirms Serie A status for another year after beating Salernitana
'Unusually cool March': Cold but clear weather for Easter weekend